Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04587713 · ClinicalTrials.gov registry record · Phase 1
Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects
A Phase 1 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT04587713 is a Phase 1 study that has completed, run by Theravance Biopharma. The registered enrollment target is 58 participants.
The verdict
NCT04587713, a Phase 1 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
This is a Phase 1, 2-part, open-label study. Part A will be a formulation bridging and food effect study in healthy adult subjects. Part B will be an assessment of pharmacokinetics (PK) in healthy adult Chinese subjects.
Interventions
- DRUG TD-1473 [Tablet A]
- DRUG TD-1473 [Tablet B]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2020-10-16 |
| Est. Completion | 2020-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04587713
The ClinicalTrials.gov registry entry for NCT04587713 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TD-1473 [Tablet A] is the first listed.
NCT04587713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04587713 about?
NCT04587713 is a clinical study titled "Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects". This is a Phase 1, 2-part, open-label study. Part A will be a formulation bridging and food effect study in healthy adult subjects. Part B will be an assessment of pharmacokinetics (PK) in healthy adult Chinese subjects.
What is the current status of trial NCT04587713?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2020-10-16. Estimated completion is 2020-12-27.
What interventions are being tested in trial NCT04587713?
The interventions under investigation include: TD-1473 [Tablet A] (DRUG), TD-1473 [Tablet B] (DRUG).
Who is sponsoring clinical trial NCT04587713?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.